Glenmark Pharmaceuticals’ biotech arm -- Ichnos Glenmark Innovation, Inc. (IGI) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (USFDA) for ISB 2301. ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens and engage both T cells and NK cells. This pentaspecific molecule combines five binding specificities: three tumor-associated antigens, plus T-cell and NK-cell activation. By combining tumor-cell recognition with complementary immune activity, ISB 2301 is being developed to address biological heterogeneity and immune-suppressive features of solid tumors.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.